Circulating inflammatory cytokines and adipokines are associated with increased risk of Barrett's esophagus: a case-control study.

PubWeight™: 1.29‹?› | Rank: Top 10%

🔗 View Article (PMC 3899092)

Published in Clin Gastroenterol Hepatol on August 15, 2013

Authors

Jose M Garcia1, Andres E Splenser2, Jennifer Kramer3, Abeer Alsarraj3, Stephanie Fitzgerald3, David Ramsey3, Hashem B El-Serag4

Author Affiliations

1: Department of Medicine, Michael E. DeBakey Veterans Affairs Medical Center, Houston, Texas; Department of Medicine, Baylor College of Medicine, Houston, Texas; Huffington Center on Aging, Baylor College of Medicine, Houston, Texas.
2: Department of Medicine, Michael E. DeBakey Veterans Affairs Medical Center, Houston, Texas; Department of Medicine, Baylor College of Medicine, Houston, Texas.
3: Department of Medicine, Baylor College of Medicine, Houston, Texas; VA Health Services Research and Development Center of Excellence, Houston, Texas.
4: Department of Medicine, Michael E. DeBakey Veterans Affairs Medical Center, Houston, Texas; Department of Medicine, Baylor College of Medicine, Houston, Texas; VA Health Services Research and Development Center of Excellence, Houston, Texas. Electronic address: hasheme@bcm.edu.

Articles citing this

Epidemiology, Diagnosis, and Management of Esophageal Adenocarcinoma. Gastroenterology (2015) 1.21

A multibiomarker risk score helps predict risk for Barrett's esophagus. Clin Gastroenterol Hepatol (2013) 1.07

Associations of Serum Adiponectin and Leptin With Barrett's Esophagus. Clin Gastroenterol Hepatol (2015) 1.03

Association of Serum Levels of Adipokines and Insulin With Risk of Barrett's Esophagus: A Systematic Review and Meta-Analysis. Clin Gastroenterol Hepatol (2015) 1.02

Adiponectin May Modify the Risk of Barrett's Esophagus in Patients With Gastroesophageal Reflux Disease. Clin Gastroenterol Hepatol (2015) 0.98

The role of obesity in oesophageal cancer development. Therap Adv Gastroenterol (2014) 0.90

Physical activity is associated with reduced risk of esophageal cancer, particularly esophageal adenocarcinoma: a systematic review and meta-analysis. BMC Gastroenterol (2014) 0.87

Pathophysiological mechanisms linking obesity and esophageal adenocarcinoma. World J Gastrointest Pathophysiol (2014) 0.84

The effect of abdominal visceral fat, circulating inflammatory cytokines, and leptin levels on reflux esophagitis. J Neurogastroenterol Motil (2015) 0.84

Metformin does not reduce markers of cell proliferation in esophageal tissues of patients with Barrett's esophagus. Clin Gastroenterol Hepatol (2014) 0.83

Metabolic syndrome and the risk of Barrett's oesophagus in white males. Aliment Pharmacol Ther (2015) 0.82

Inverse Association Between Gluteofemoral Obesity and Risk of Barrett's Esophagus in a Pooled Analysis. Clin Gastroenterol Hepatol (2016) 0.81

Screening for Barrett's esophagus and esophageal adenocarcinoma: rationale, recent progress, challenges, and future directions. Clin Gastroenterol Hepatol (2014) 0.81

Barrett's esophagus suspected at endoscopy but no specialized intestinal metaplasia on biopsy, what's next? Am J Gastroenterol (2013) 0.81

Non-Alcoholic Fatty Liver Disease and Extra-Hepatic Cancers. Int J Mol Sci (2016) 0.80

Epidemiology of Barrett's Esophagus and Esophageal Adenocarcinoma. Gastroenterol Clin North Am (2015) 0.79

No increase in gastric acid secretion in healthy Japanese over the past two decades. J Gastroenterol (2014) 0.79

Obesity-Related Digestive Diseases and Their Pathophysiology. Gut Liver (2016) 0.78

Associations of Circulating Gut Hormone and Adipocytokine Levels with the Spectrum of Gastroesophageal Reflux Disease. PLoS One (2015) 0.76

Esophageal COX-2 expression is increased in Barrett's esophagus, obesity, and smoking. Dig Dis Sci (2014) 0.75

Barrett's Oesophagus in an Achalasia Patient: Immunological Analysis and Comparison with a Group of Achalasia Patients. Case Rep Gastrointest Med (2016) 0.75

Circulating Inflammatory Cytokines Are Associated With the Risk of Barrett's Esophagus in Western Persons. J Neurogastroenterol Motil (2014) 0.75

Contribution of immunomodulators to gastroesophageal reflux disease and its complications: stromal cells, interleukin 4, and adiponectin. Ann N Y Acad Sci (2016) 0.75

Recent developments in pathogenesis, diagnosis and therapy of Barrett's esophagus. World J Gastroenterol (2015) 0.75

Alteration of Esophageal Microbiome by Antibiotic Treatment Does Not Affect Incidence of Rat Esophageal Adenocarcinoma. Dig Dis Sci (2016) 0.75

Articles cited by this

Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest (2003) 32.01

Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nat Rev Cancer (2004) 16.69

The role of overdiagnosis and reclassification in the marked increase of esophageal adenocarcinoma incidence. J Natl Cancer Inst (2005) 8.90

Prevalence and clinical spectrum of gastroesophageal reflux: a population-based study in Olmsted County, Minnesota. Gastroenterology (1997) 8.51

Abnormal splicing of the leptin receptor in diabetic mice. Nature (1996) 7.71

cDNA cloning and expression of a novel adipose specific collagen-like factor, apM1 (AdiPose Most abundant Gene transcript 1). Biochem Biophys Res Commun (1996) 5.40

Association of hypoadiponectinemia with coronary artery disease in men. Arterioscler Thromb Vasc Biol (2003) 4.86

Diabetes, obesity, and the brain. Science (2005) 4.59

Meta-analysis: obesity and the risk for gastroesophageal reflux disease and its complications. Ann Intern Med (2005) 4.52

Abdominal obesity and body mass index as risk factors for Barrett's esophagus. Gastroenterology (2007) 3.94

Adiponectin and metabolic syndrome. Arterioscler Thromb Vasc Biol (2003) 3.78

Epidemiologic trends in esophageal and gastric cancer in the United States. Surg Oncol Clin N Am (2002) 3.69

A critical review of the diagnosis and management of Barrett's esophagus: the AGA Chicago Workshop. Gastroenterology (2004) 3.50

Adiponectin stimulates AMP-activated protein kinase in the hypothalamus and increases food intake. Cell Metab (2007) 3.43

Adiponectin: more than just another fat cell hormone? Diabetes Care (2003) 3.30

A new questionnaire for gastroesophageal reflux disease. Mayo Clin Proc (1994) 3.14

A systematic review and meta-analysis of the risk of increasing adiposity on Barrett's esophagus. Am J Gastroenterol (2007) 2.79

Abdominal obesity and the risk of Barrett's esophagus. Am J Gastroenterol (2005) 2.60

A pilot study of the association of low plasma adiponectin and Barrett's esophagus. Am J Gastroenterol (2008) 2.39

Adiponectin and cancer: a systematic review. Br J Cancer (2006) 2.33

Bile acid and inflammation activate gastric cardia stem cells in a mouse model of Barrett-like metaplasia. Cancer Cell (2012) 2.16

The importance of interleukin 1beta in Helicobacter pylori associated disease. Gut (2001) 2.02

Plasma adiponectin concentration is associated with skeletal muscle insulin receptor tyrosine phosphorylation, and low plasma concentration precedes a decrease in whole-body insulin sensitivity in humans. Diabetes (2002) 1.94

Central adiposity is associated with increased risk of esophageal inflammation, metaplasia, and adenocarcinoma: a systematic review and meta-analysis. Clin Gastroenterol Hepatol (2013) 1.56

Prediction of malignant potential in reflux disease: are cytokine polymorphisms important? Am J Gastroenterol (2005) 1.54

Leptin and the risk of Barrett's oesophagus. Gut (2008) 1.54

Association of adiponectin multimers with Barrett's oesophagus. Gut (2009) 1.43

Waist-to-hip ratio, but not body mass index, is associated with an increased risk of Barrett's esophagus in white men. Clin Gastroenterol Hepatol (2012) 1.41

Inflammatory gradient in Barrett's oesophagus: implications for disease complications. Gut (2002) 1.38

IL-1 plays an important role in lipid metabolism by regulating insulin levels under physiological conditions. J Exp Med (2003) 1.32

Leptin receptor action in hepatic cells. J Biol Chem (1997) 1.29

Association between markers of obesity and progression from Barrett's esophagus to esophageal adenocarcinoma. Clin Gastroenterol Hepatol (2013) 1.29

Hypothalamic leptin regulation of energy homeostasis and glucose metabolism. J Physiol (2007) 1.26

Tumour necrosis factor-alpha in Barrett's oesophagus: a potential novel mechanism of action. Oncogene (2002) 1.25

Measuring circulating cytokines. J Appl Physiol (1985) (1993) 1.25

Trends in incidence and prevalence of specialized intestinal metaplasia, barrett's esophagus, and adenocarcinoma of the gastroesophageal junction. World J Surg (2003) 1.23

Serum leptin and adiponectin levels and risk of Barrett's esophagus and intestinal metaplasia of the gastroesophageal junction. Obesity (Silver Spring) (2010) 1.18

Role of obesity in GORD-related disorders. Gut (2008) 1.17

Visceral abdominal obesity measured by CT scan is associated with an increased risk of Barrett's oesophagus: a case-control study. Gut (2013) 1.14

Association of insulin and insulin-like growth factors with Barrett's oesophagus. Gut (2011) 1.13

Aspirin protects against Barrett's esophagus in a multivariate logistic regression analysis. Clin Gastroenterol Hepatol (2012) 1.09

Effect of adiponectin and ghrelin on apoptosis of Barrett adenocarcinoma cell line. Dig Dis Sci (2007) 0.98

A pro-inflammatory genotype predisposes to Barrett's esophagus. Carcinogenesis (2008) 0.98

Leptin in anorexia and cachexia syndrome. Int J Pept (2012) 0.96

Leptin synergistically enhances the anti-apoptotic and growth-promoting effects of acid in OE33 oesophageal adenocarcinoma cells in culture. Mol Cell Endocrinol (2007) 0.93

Physiological regulation of hypothalamic IL-1beta gene expression by leptin and glucocorticoids: implications for energy homeostasis. Am J Physiol Endocrinol Metab (2004) 0.92

Cancer-related inflammation and Barrett's carcinogenesis: interleukin-6 and STAT3 mediate apoptotic resistance in transformed Barrett's cells. Am J Physiol Gastrointest Liver Physiol (2010) 0.92

Leptin stimulates the proliferation of human oesophageal adenocarcinoma cells via HB-EGF and Tgfalpha mediated transactivation of the epidermal growth factor receptor. Br J Biomed Sci (2008) 0.83

Role of Th-2 cytokines in the development of Barrett's esophagus in rats. J Gastroenterol (2011) 0.82

Epigenomic program of Barrett's-associated neoplastic progression reveals possible involvement of insulin signaling pathways. Endocr Relat Cancer (2012) 0.82

Expression of IFN-γ and IL-4 in the esophageal mucosa of patients with reflux esophagitis and Barrett's esophagus and their relationship with endoscopic and histologic grading. Dig Dis Sci (2011) 0.81